Abstract: There is provided a syringe capable of preventing the occurrence of “link-thread” from the distal end nozzle when the cap is pulled out, even in the case where the medicinal liquid filled has a high viscosity. The inner peripheral surface (631) of the seal cap (63) in the cap (6) is brought into close contact with the outer peripheral surface (214) of the distal end side portion of the distal end nozzle (21) in the barrel (2) so that the distal end opening (211) is hermetically closed off. At the same time, the outer peripheral side of the luer lock adapter (22) is covered with the outer tubular cover (62) of the cap. The bulge part (213) is formed in the distal end side portion of the inner aperture (212) in the distal end nozzle so that the aperture diameter (d) of the distal end opening is reduced to a small aperture diameter and, in addition, the length of seal (s) by the seal cap (63) is made to be a relatively short, predetermined length.

Abstract: Provided are a polyvinyl acetal sheet which is excellent in adhesion to glass, easy in control of adhesion, little colored, highly transparent and excellent in penetration resistance even under high-temperature conditions when the sheet is used for laminated glass or the like, a process for its production and a process for producing polyvinyl acetal particles used for the sheet. The polyvinyl acetal sheet is produced by molding polyvinyl acetal particles into a sheet with a degree of acetalization of from 75.0 to 84.0 mass % and with a porosity of from 60 to 85%. The polyvinyl acetal particles are preferably produced by an acetalization reaction of 100 parts by mass of a polyvinyl alcohol and from 40 to 75 parts by mass of an aldehyde in the presence of an acid catalyst at a reaction temperature of from 20 to 60° C.

Abstract: FR-900493 is a compound of molecular formula C.sub.20 H.sub.33 N.sub.5 O.sub.11 which may be recovered from Bacillus cultures, possesses antimicrobial activity, and may be used for the treatment and prevention of infectious diseases in humans and animals.

Abstract: This invention relates to a method for promoting the growth of growing animals with compounds selected from WS-1627A; WS-1627B; WS-1627C and WS-1627D or salts thereof.

Abstract: The invention relates to a method for treatment of carcinoma or sarcoma tumor in mammals which comprises administering to said mammal an effective amount of a tetracyclo compound of the formula: ##STR1## in which R.sup.1 is formyl, protected formyl, hydroxymethyl, protected hydroxymethyl, arylaminomethyl, carboxy, protected carboxy, aryliminomethyl, hydroxyiminomethyl, alkoxyiminomethyl, acyloxyiminomethyl, semicarbazonomethyl or arylsemicarbazonomethyl,R.sup.2 is hydroxy, alkoxy, or protected hydroxy,R.sup.3 is hydrogen and R.sup.4 is methyl, hydroxymethyl or protected hydroxymethyl, orR.sup.3 and R.sup.4 are combined together to form methylene or oxo,R.sup.5 is hydroxy, alkoxy or protected hydroxy, andR.sup.6 is hydrogen, imino-protective group or alkyl,and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to novel peptides, of pharmacological activity, of the formula: ##STR1## wherein R.sup.1 is hydrogen,R.sub.b.sup.1 is methyl,R.sup.2 is carboxy, carboxymethylcarbamoyl, 1-carboxyethylcarbamoyl or ethoxycarbonylmethylcarbamoyl,R.sup.q is carboxy or 3-t-butoxycarbonylcarbazoyl,R.sup.p is carboxy or methoxycarbonyl,R.sup.r is hydrogen, t-butoxycarbonyl or benzyloxycarbonyl,m is the integer 2, andn is the integer 1, or its pharmaceutically acceptable salt.

Abstract: The invention relates to novel furanone derivatives, having an aldose reductase-inhibitory activity, of the formula ##STR1## wherein A is a lower alkylene group,R.sup.1 is a carboxy, hydroxy, protected hydroxy or lower alkoxycarbonyl group,R.sup.2 is a hydrogen or halogen atom or a halo (lower) alkyl group, andR.sup.3 is a hydrogen atom or a hydroxy, carboxy, lower alkoxy or lower alkoxycarbonyl group.

Abstract: The invention relates to compounds of antihypertensive and antithrombotic activity of the formula or its pharmaceutically acceptable salt: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, or lower alkoxyphenyl,R.sup.2 is hydrogen or lower alkyl,R.sup.4 is lower alkyl,R.sup.6 is hydrogen or lower alkyl,R.sup.7 is lower alkyl which is optionally substituted by hydroxy or lower alkanoyloxy, andR.sup.10 is hydrogen or lower alkyl which is optionally substituted by carboxy or esterified carboxy.

Abstract: New nitro aliphatic compounds and their pharmaceutically acceptable salts are disclosed.

Abstract: New Nitro aliphatic compounds and their pharmaceutically acceptable salts are disclosed.

Abstract: The invention relates to novel peptides of enhanced pharmacological activity of the formula: ##STR1## wherein R.sup.1 is hydroxyalkanoyl,R.sup.2 and R.sup.q are each hydrogen, carboxy, protected carboxy, or a group of the formula: ##STR2## wherein R.sub.a.sup.2 is mono- or di-carboxy (or protected carboxy) lower alkyl or ar(carboxy or protected carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy, R.sup. 2 is hydrogen or lower alkyl; R.sup.p is hydrogen, carboxy, protected carboxy, with proviso that when one of R.sup.2 and R.sup.q is hydrogen, then the other is carboxy or protected carboxy or a group of the formula: ##STR3## wherein R.sub.a.sup.2 and R.sub.b.sup.2 are each as defined above; R.sup.r is hydrogen or amino protective group; m is an integer 1 to 3;or its pharmaceutically acceptable salt.

Abstract: A biologically pure culture of Streptomyces sandaensis which is capable of producing an antitumor and antimicrobial compound, designated FR-900482 substance, is disclosed.

Abstract: Novel compounds of the following formula have restorative pharmacological activities in immuno-deficient hosts, ##STR1## wherein R.sup.1 is amino or a protected amino group,R.sup.2 is hydrogen, carboxy or a protected carboxy group,R.sup.3 is hydrogen, carboxy or a protected carboxy group,R.sup.4 is lower alkyl, amino(lower)alkyl, protected amino(lower)alkyl, carbamoyl(lower)alkyl or protected carbamoyl(lower)alkyl,R.sup.5 is hydrogen or lower alkyl, andR.sup.6 is hydrogen, hydroxyphenyl(lower)alkyl, imidazolyl(lower)alkyl or indolyl(lower)alkyl.

Abstract: The invention concerns peptides, having the pharmaceutical property of enhancing the immune response, having the structure: ##STR1## wherein R.sup.1 is alkanoyl,R.sub.b.sup.1 is hydrogen, methyl, isopropyl, hydroxymethyl, protected hydroxymethyl or benzyl,R.sup.2 is hydrogen, carboxy, protected carboxy or a group of the formula: ##STR2## wherein R.sub.a.sup.2 is mono- or di-carboxy (or protected carboxy) lower alkyl or ar(carboxy or protected carboxy) lower alkyl whose aryl moiety is substituted by hydroxy or not substituted,R.sub.b.sup.2 is hydrogen or lower alkyl,R.sup.p is hydrogen, carboxy or protected carboxy,R.sup.q is carboxy, protected carboxy or a group of the formula ##STR3## wherein R.sub.a.sup.2 and R.sub.b.sup.2 are each as defined above, R.sup.r is hydrogen or amino protective group,m is an integer 1 to 3, andn is an integer 1.

Abstract: The invention relates to a pharmaceutical composition for treating lymphocytic leukemia, melanoma or mammary carcinoma comprising an effective amount of FR-900216.

Abstract: The invention relates to a new compound, designated FR-68504. The compound has antitimor activities and is effective in the treatment of various tumors in both human beings and animals.There is also provided a process for preparing FR-68504 compound which comprises culturing a FR-68504 producing strain belonging to the genus Amauroascus in a nutrient medium.Pharmaceutical composition comprising FR-68504 as an active ingredient is also described.

Abstract: The invention relates to novel peptides of enhanced pharmacological activity of the formula: ##STR1## wherein R.sup.1 is alkanoyl;R.sup.2 and R.sup.q are each hydrogen, carboxy, protected carboxy, or a group of the formula: ##STR2## wherein R.sub.a.sup.2 is mono- or di-carboxy (or protected carboxy) lower alkyl or ar(carboxy or protected carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy,R.sub.b.sup.2 is hydrogen or lower alkyl;R.sup.P is hydrogen, carboxy, protected carboxy, with proviso that when one of R.sup.2 and R.sup.q is hydrogen, then the other is carboxy or protected carboxy or a group of the formula: ##STR3## wherein R.sub.a.sup.2 and R.sub.b.sup.2 are each as defined above; R.sup.r is hydrogen or amino protective group;m is an integer 1 to 3;or its pharmaceutically acceptable salt.

Abstract: This invention relates to a biologically active WS-7739-A substance and a biologically active WS-7739-B substance which have pharmacological activities and are useful for the treatment of asthma, thrombosis and the alike.

Abstract: Antibiotic FR-900451 is produced by Streptomyces griseorubiginosus No. 43708 (FERM BP-699).

Abstract: The invention deals with novel peptides useful for the therapeutic treatment of infectious diseases caused by pathogenic microorganisms. Included is the peptide FR900156 having the structure: ##STR1## as well as the peptides of the structure ##STR2## wherein R.sup.1 is acyl;R.sub.b.sup.1 is hydrogen, methyl, isopropyl, hydroxymethyl, protected hydroxymethyl or benzyl;R.sup.2 is hydrogen, carboxy, protected carboxy, or a group of the formula: ##STR3## wherein R.sub.a.sup.2 is mono- or di-carboxy lower alkyl or ar(carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy,R.sub.b.sup.2 is hydrogen or lower alkyl;R.sup.p and R.sup.q are each hydrogen, carboxy, protected carboxy, with proviso that when one of R.sup.2 and R.sup.q is hydrogen, then the other is carboxy or protected carboxy;R.sup.r is hydrogen or amino protective group; m is an integer 1 to 3, and n is 1 .Iadd.provided that when R.sup.1 is benzyloxycarbonyl R.sub.5.sup.1 is methyl, m is an integer 2 and n is an integer 1, then R.sup.